Compare BZUN & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BZUN | SABS |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 176.9M | 181.4M |
| IPO Year | N/A | N/A |
| Metric | BZUN | SABS |
|---|---|---|
| Price | $2.69 | $3.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 201.3K | ★ 253.6K |
| Earning Date | 11-25-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,372,022,139.00 | $114,698.00 |
| Revenue This Year | $5.92 | N/A |
| Revenue Next Year | $3.80 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.08 | N/A |
| 52 Week Low | $2.12 | $1.00 |
| 52 Week High | $4.88 | $6.60 |
| Indicator | BZUN | SABS |
|---|---|---|
| Relative Strength Index (RSI) | 35.45 | 59.35 |
| Support Level | $2.73 | $3.54 |
| Resistance Level | $2.87 | $4.08 |
| Average True Range (ATR) | 0.15 | 0.30 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 23.96 | 75.28 |
Baozun Inc is engaged to provide its customers with end-to-end e-commerce solutions including the sales of apparel, home and electronic products, online store design and setup, visual merchandising and marketing, online store operations, customer services, warehousing and order fulfillment, as well as the holistic brand management, including strategy and tactic positioning, branding and marketing, retail and e-commerce operations, supply chain and logistics, and technology empowerment. It has two operating segments: E-Commerce (encompassing BEC and BZI) and Brand Management (representing BBM). The company generates maximum of its revenue from E-Commerce (encompassing BEC and BZI) segment.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.